cfDNA Integrity in Early Cancer Detection: A Review Article
The Journal of Iraqi Society of Pharmaceutical Sciences (ISSN 3136-9618) · 12.07.2026 · 1 (1) · 1-6
DOI: 10.68889/jisps.v1i1.a3 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Iraqi Society of Pharmaceutical Sciences (ISSN 3136-9618), online erschienen am 12.07.2026. Verfasst von Saad Abdul Kareem Mohammed und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Background
Cell-free DNA (cfDNA) carries genetic and epigenetic information from its cells of origin. The integrity of cfDNA is the ratio of longer to shorter DNA fragments. It has emerged as a promising non-invasive biomarker for cancer diagnosis.
Objective
To synthesize current evidence on the diagnostic performance of cfDNA integrity in early cancer detection.
Methods
A comprehensive literature search was conducted in PubMed, Scopus, and Web of Science (2015–2026). Keywords related to cfDNA integrity, cancer, and diagnostics were used. Studies reporting quantitative integrity indices (e.g., ALU247/ALU115 ratio and LINE 1 fragments) and diagnostic accuracy metrics were included.
Results
A total of 98 studies were analyzed. The cell-free DNA (cfDNA) integrity index (cfDI) was elevated in patients with lung, colorectal, breast, hepatocellular, and ovarian cancer compared with healthy subjects. Sensitivity ranges from 55% to 88%, and specificity from 70% to 95%, depending on the cancer type and cutoff. Combination with other markers (e.g., protein biomarkers, DNA methylation panels) improves performance. However, pre-analytical variability, the lack of standardized integrity metrics, and inter-study heterogeneity limit the current clinical utility. Conclusions: cfDNA integrity holds considerable potential as an adjunctive tool for early cancer detection. Standardization of pre-analytical and analytical workflows is essential, along with large-scale prospective validation, before integration into routine clinical practice.
Zitieren
APA
Mohammed, S. A. K., Owaid, A. S., Abdaljabar, T. T., Jabbar, E. G., Mohammed, A. S. A. K., & Mohammed, A. S. A. K. (2026). cfDNA Integrity in Early Cancer Detection: A Review Article. The Journal of Iraqi Society of Pharmaceutical Sciences (ISSN 3136-9618), 1(1), 1-6. https://doi.org/10.68889/jisps.v1i1.a3
Vancouver
Mohammed SAK, Owaid AS, Abdaljabar TT, Jabbar EG, Mohammed ASAK, Mohammed ASAK. cfDNA Integrity in Early Cancer Detection: A Review Article. The Journal of Iraqi Society of Pharmaceutical Sciences (ISSN 3136-9618). 2026;1(1):1-6. doi:10.68889/jisps.v1i1.a3
BibTeX
@article{Mohammed2026,
author = {Mohammed, Saad Abdul Kareem and Owaid, Adil Salim and Abdaljabar, Tariq Talal and Jabbar, Esraa Ghazy and Mohammed, Ali Saad Abdul Kareem and Mohammed, Abdulla Saad Abdul Kareem},
title = {cfDNA Integrity in Early Cancer Detection: A Review Article},
journal = {The Journal of Iraqi Society of Pharmaceutical Sciences (ISSN 3136-9618)},
year = {2026},
volume = {1},
number = {1},
pages = {1--6},
doi = {10.68889/jisps.v1i1.a3}
}
EUVIMED